TRPV1 and Guillain-Barre syndrome: Regarding the positive and negative sensory deficits displayed in GBS and EAN, Wei et al. [16] found compelling evidence that kinesin-5 inhibition reversed pathological pain by inhibiting vanilloid receptor subtype 1 (VR1) axonal trafficking.